Aktieanalys

Gasporox Q1 2024: Just as expected - Redeye

Redeye Publicerad: 23 Apr 08:54

Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA seven consecutive quarters in a row, thus trending towards profitability. Sales were driven by VialArch, GPX1500 Vial, and after-sales. Gasporox, with SEK10.4m in cash and SEK12.8m in working capital, is financially stable but faces risks with a convertible loan that could be settled in cash if shares fall below SEK8.5. However, significant stakeholders might opt to increase their shares, and a non-specific contingency plan exists for such settlements.

Länk till analysen i sin helhet: https://www.redeye.se/research/997065/gasporox-q1-2024-just-as-expected?utm_source=finwire&utm_medium=RSS

Nyheter om Gasporox

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!